MFSD2A and infection: For in vivo infection, an AAV overexpressing Mfsd2a (2 μl, 1.2*1012 viral genomes/mL) or a control virus (2 μl, 1.3*1012 viral genomes/mL) was administered via intracerebroventricular injection using a slow infusion rate of 100 nl/min.